Guardant Health

Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, contingent consideration, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non-marketable equity securities, among others.

SEC original ↗Guardant Health — 10-Q Quarterly report10-QJul 30, 2026

The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.

SEC original ↗Guardant Health — 10-Q Quarterly report10-QJul 30, 2026

The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate.

SEC original ↗Guardant Health — 10-Q Quarterly report10-QJul 30, 2026

Treasury Stock Treasury stock is accounted for at cost based on the amount paid to repurchase the Company's common stock, and is recorded as a reduction of the Company's stockholders equity.

SEC original ↗Guardant Health — 10-Q Quarterly report10-QJul 30, 2026

Direct costs incurred to repurchase the Company's common stock are included in the cost of the treasury stock.

SEC original ↗Guardant Health — 10-Q Quarterly report10-QJul 30, 2026

The Black-Scholes option-pricing model requires assumptions to be made related to the expected term of an award, expected volatility, risk-free rate and expected dividend yield.

SEC original ↗Guardant Health — 10-Q Quarterly report10-QJul 30, 2026

Product innovation built on Smart Liquid Biopsy is integral to our strategy at Guardant and we look forward to continuing a steady cadence of SLB-based applications to further extend our technical leadership in the comprehensive genomic profiling market.

SEC original ↗Guardant Health — Earnings release (8-K exhibit)EX-99Jul 30, 2025

The year-over-year increase in operating expenses was primarily related to commercial team expansion and marketing activities to support the Shield product launch and existing products, as well as an increase in stock-based compensation expense.

SEC original ↗Guardant Health — Earnings release (8-K exhibit)EX-99Jul 30, 2025

The year-over-year increase in non-GAAP operating expenses was primarily related to commercial team expansion and marketing activities to support the Shield product launch and existing products.

SEC original ↗Guardant Health — Earnings release (8-K exhibit)EX-99Jul 30, 2025

About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.

SEC original ↗Guardant Health — Earnings release (8-K exhibit)EX-99Jul 30, 2025

, or the Company, is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.

SEC original ↗Guardant Health — 10-Q Quarterly report10-QJul 30, 2026

Forward Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements.

SEC original ↗Guardant Health — Earnings release (8-K exhibit)EX-99Jul 30, 2025

These and additional risks and uncertainties that could affect Guardant Health s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operation and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter.

SEC original ↗Guardant Health — Earnings release (8-K exhibit)EX-99Jul 30, 2025

Legal Proceedings 52 Item 1A.

SEC original ↗Guardant Health — 10-Q Quarterly report10-QJul 30, 2026

These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to risks, uncertainties and assumptions that are difficult to predict.

SEC original ↗Guardant Health — 10-Q Quarterly report10-QJul 30, 2026

and the University of Washington, as described in Note 9, Commitments and Contingencies - Legal Proceedings to the Company's condensed consolidated financial statements.

SEC original ↗Guardant Health — 10-Q Quarterly report10-QJul 30, 2026

Both the estimate and any subsequent revision contain uncertainty and require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration.

SEC original ↗Guardant Health — 10-Q Quarterly report10-QJul 30, 2026